Pt(IV) complexes as prodrugs for cisplatin

Yi Shi, Shu An Liu, Deborah J. Kerwood, Jerry Goodisman, James C. Dabrowiak

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are believed to be due to biological reduction of Pt(IV) to Pt(II), with the reduction products binding to DNA and other cellular targets. In this work we used pBR322 DNA to capture the products of reduction of oxoplatin, c,t,c-[PtCl 2(OH) 2(NH 3) 2], 3, and a carboxylate-modified analog, c,t,c-[PtCl 2(OH)(O 2CCH 2CH 2CO 2H)(NH 3) 2], 4, by ascorbic acid (AsA) or glutathione (GSH). Since carbonate plays a significant role in the speciation of platinum complexes in solution, we also investigated the effects of carbonate on the reduction/DNA-binding process. In pH 7.4 buffer in the absence of carbonate, both 3 and 4 are reduced by AsA to cisplatin (confirmed using 195Pt NMR), which binds to and unwinds closed circular DNA in a manner consistent with the formation of the well-known 1, 2 intrastrand DNA crosslink. However, when GSH is used as the reducing agent for 3 and 4, 195Pt NMR shows that cisplatin is not produced in the reaction medium. Although the Pt(II) products bind to closed circular DNA, their effect on the mobility of Form I DNA is different from that produced by cisplatin. When physiological carbonate is present in the reduction medium, 13C NMR shows that Pt(II) carbonato complexes form which block or impede platinum binding to DNA. The results of the study vis-à-vis the ability of the Pt(IV) complexes to act as prodrugs for cisplatin are discussed.

Original languageEnglish (US)
Pages (from-to)6-14
Number of pages9
JournalJournal of Inorganic Biochemistry
Volume107
Issue number1
DOIs
StatePublished - Feb 2012

Fingerprint

Prodrugs
Cisplatin
Carbonates
DNA
Platinum
Circular DNA
Nuclear magnetic resonance
Ascorbic Acid
Reducing Agents
Glutathione
Buffers

ASJC Scopus subject areas

  • Biochemistry
  • Inorganic Chemistry

Cite this

Shi, Y., Liu, S. A., Kerwood, D. J., Goodisman, J., & Dabrowiak, J. C. (2012). Pt(IV) complexes as prodrugs for cisplatin. Journal of Inorganic Biochemistry, 107(1), 6-14. https://doi.org/10.1016/j.jinorgbio.2011.10.012

Pt(IV) complexes as prodrugs for cisplatin. / Shi, Yi; Liu, Shu An; Kerwood, Deborah J.; Goodisman, Jerry; Dabrowiak, James C.

In: Journal of Inorganic Biochemistry, Vol. 107, No. 1, 02.2012, p. 6-14.

Research output: Contribution to journalArticle

Shi, Y, Liu, SA, Kerwood, DJ, Goodisman, J & Dabrowiak, JC 2012, 'Pt(IV) complexes as prodrugs for cisplatin', Journal of Inorganic Biochemistry, vol. 107, no. 1, pp. 6-14. https://doi.org/10.1016/j.jinorgbio.2011.10.012
Shi, Yi ; Liu, Shu An ; Kerwood, Deborah J. ; Goodisman, Jerry ; Dabrowiak, James C. / Pt(IV) complexes as prodrugs for cisplatin. In: Journal of Inorganic Biochemistry. 2012 ; Vol. 107, No. 1. pp. 6-14.
@article{4fbe36ebf16444388ca69ec5719a0f3e,
title = "Pt(IV) complexes as prodrugs for cisplatin",
abstract = "The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are believed to be due to biological reduction of Pt(IV) to Pt(II), with the reduction products binding to DNA and other cellular targets. In this work we used pBR322 DNA to capture the products of reduction of oxoplatin, c,t,c-[PtCl 2(OH) 2(NH 3) 2], 3, and a carboxylate-modified analog, c,t,c-[PtCl 2(OH)(O 2CCH 2CH 2CO 2H)(NH 3) 2], 4, by ascorbic acid (AsA) or glutathione (GSH). Since carbonate plays a significant role in the speciation of platinum complexes in solution, we also investigated the effects of carbonate on the reduction/DNA-binding process. In pH 7.4 buffer in the absence of carbonate, both 3 and 4 are reduced by AsA to cisplatin (confirmed using 195Pt NMR), which binds to and unwinds closed circular DNA in a manner consistent with the formation of the well-known 1, 2 intrastrand DNA crosslink. However, when GSH is used as the reducing agent for 3 and 4, 195Pt NMR shows that cisplatin is not produced in the reaction medium. Although the Pt(II) products bind to closed circular DNA, their effect on the mobility of Form I DNA is different from that produced by cisplatin. When physiological carbonate is present in the reduction medium, 13C NMR shows that Pt(II) carbonato complexes form which block or impede platinum binding to DNA. The results of the study vis-{\`a}-vis the ability of the Pt(IV) complexes to act as prodrugs for cisplatin are discussed.",
author = "Yi Shi and Liu, {Shu An} and Kerwood, {Deborah J.} and Jerry Goodisman and Dabrowiak, {James C.}",
year = "2012",
month = "2",
doi = "10.1016/j.jinorgbio.2011.10.012",
language = "English (US)",
volume = "107",
pages = "6--14",
journal = "Journal of Inorganic Biochemistry",
issn = "0162-0134",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Pt(IV) complexes as prodrugs for cisplatin

AU - Shi, Yi

AU - Liu, Shu An

AU - Kerwood, Deborah J.

AU - Goodisman, Jerry

AU - Dabrowiak, James C.

PY - 2012/2

Y1 - 2012/2

N2 - The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are believed to be due to biological reduction of Pt(IV) to Pt(II), with the reduction products binding to DNA and other cellular targets. In this work we used pBR322 DNA to capture the products of reduction of oxoplatin, c,t,c-[PtCl 2(OH) 2(NH 3) 2], 3, and a carboxylate-modified analog, c,t,c-[PtCl 2(OH)(O 2CCH 2CH 2CO 2H)(NH 3) 2], 4, by ascorbic acid (AsA) or glutathione (GSH). Since carbonate plays a significant role in the speciation of platinum complexes in solution, we also investigated the effects of carbonate on the reduction/DNA-binding process. In pH 7.4 buffer in the absence of carbonate, both 3 and 4 are reduced by AsA to cisplatin (confirmed using 195Pt NMR), which binds to and unwinds closed circular DNA in a manner consistent with the formation of the well-known 1, 2 intrastrand DNA crosslink. However, when GSH is used as the reducing agent for 3 and 4, 195Pt NMR shows that cisplatin is not produced in the reaction medium. Although the Pt(II) products bind to closed circular DNA, their effect on the mobility of Form I DNA is different from that produced by cisplatin. When physiological carbonate is present in the reduction medium, 13C NMR shows that Pt(II) carbonato complexes form which block or impede platinum binding to DNA. The results of the study vis-à-vis the ability of the Pt(IV) complexes to act as prodrugs for cisplatin are discussed.

AB - The antitumor effects of platinum(IV) complexes, considered prodrugs for cisplatin, are believed to be due to biological reduction of Pt(IV) to Pt(II), with the reduction products binding to DNA and other cellular targets. In this work we used pBR322 DNA to capture the products of reduction of oxoplatin, c,t,c-[PtCl 2(OH) 2(NH 3) 2], 3, and a carboxylate-modified analog, c,t,c-[PtCl 2(OH)(O 2CCH 2CH 2CO 2H)(NH 3) 2], 4, by ascorbic acid (AsA) or glutathione (GSH). Since carbonate plays a significant role in the speciation of platinum complexes in solution, we also investigated the effects of carbonate on the reduction/DNA-binding process. In pH 7.4 buffer in the absence of carbonate, both 3 and 4 are reduced by AsA to cisplatin (confirmed using 195Pt NMR), which binds to and unwinds closed circular DNA in a manner consistent with the formation of the well-known 1, 2 intrastrand DNA crosslink. However, when GSH is used as the reducing agent for 3 and 4, 195Pt NMR shows that cisplatin is not produced in the reaction medium. Although the Pt(II) products bind to closed circular DNA, their effect on the mobility of Form I DNA is different from that produced by cisplatin. When physiological carbonate is present in the reduction medium, 13C NMR shows that Pt(II) carbonato complexes form which block or impede platinum binding to DNA. The results of the study vis-à-vis the ability of the Pt(IV) complexes to act as prodrugs for cisplatin are discussed.

UR - http://www.scopus.com/inward/record.url?scp=83055168314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055168314&partnerID=8YFLogxK

U2 - 10.1016/j.jinorgbio.2011.10.012

DO - 10.1016/j.jinorgbio.2011.10.012

M3 - Article

C2 - 22169035

AN - SCOPUS:83055168314

VL - 107

SP - 6

EP - 14

JO - Journal of Inorganic Biochemistry

JF - Journal of Inorganic Biochemistry

SN - 0162-0134

IS - 1

ER -